EUAA
Guardant360 CDx is the fastest CGP panel
with guideline-recommended biomarkers.1-4*
The market leader in liquid biopsy,
backed by the strongest legacy in blood-based NGS.
IVDR certified comprehensive liquid biopsy with results in 7 days2â€
For the complete intended use statement including companion diagnostic indications,
please see the Guardant360 CDx Technical Information: Guardant360CDx.com/technicalinfo
Product availability may vary depending on region.
Broadest coverage
with >92% of patients paying $0‡
Trusted by more than
15,000 oncologists
CGP, comprehensive genomic profiling; MAF, mutant allele fraction.
*Of FDA-approved comprehensive liquid biopsies as of February 2024.
†Fastest median turnaround time from sample receipt to results based on stated median turnaround times from Integra Connect data.
‡More than 92% of patients are assigned $0 by their insurance for a
Guardant360 CDx test.
Home Oncology Portfolio Partnerships European Policy